Oncología clínica

Adrian SG, Olmos VP, Martinez del Prado P, Martin AJM. Which events to consider in the study of venous thromboses in pancreatic cancer patients? Authors' reply. Eur J Intern Med. 2023. DOI:10.1016/j.ejim.2023.01.013.

Casas A, Ciruelos E, Oliveira M, Saura C, Bellet M, Pernas S, et al. Solti-1903 HOPE: Real-world clinical practice study to assess the impact of using genomic data on the next treatment decision making-choice in patients with locally advanced or metastatic breast cancer in Spain. Cancer Res. 2022; 82(4). DOI:10.1158/1538-7445.SABCS21-OT2-06-01.

Silva Cardenas DC, Pikabea Diaz F, Zumarraga Cuesta A, Lopez Santillan M, Figaredo Berjano C, Loaiza Jaramillo PL, et al. Real-world data: incidence of venous thromboembolism recurrence and bleeding among cancer patients. Thromb Res. 2022; 213: 17-17

Diaz FP, Calvo EG, Zumarraga A, Bejarano CF, Gonzalez M, Santillan ML, et al. Predicting Oncotype DX recurrence scores using clinicopathologic features: Tennessee University Nomogram: An external validation. Ann Oncol. 2022; 33: 233-233. DOI:10.1016/j.annonc.2022.03.258.

Dafni U, Soo RA, Peters S, Tsourti Z, Vervita K, Han JY, et al. Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC: A systematic review and meta-analysis. Ann Oncol. 2022; 33: 46-47. DOI:10.1016/j.annonc.2022.02.041.

de Juan VC, Dols MC, Rodriguez Abreu D, Carcereny E, Cantero A, Caro RB, et al. Determination of essential biomarkers in lung cancer: A real-world data study in Spain. Ann Oncol. 2022; 33: 50-50. DOI:10.1016/j.annonc.2022.02.048.

Provencio M, Cobo M, Rodriguez Abreu D, Calvo V, Carcereny E, Cantero A, et al. Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics. BMC Cancer. 2022; 22(1). DOI:10.1186/s12885-022-09830-8.

Dafni U, Soo RA, Peters S, Tsourti Z, Zygoura P, Vervita K, et al. Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC-a systematic review and meta-analysis. ESMO Open. 2022; 7(3). DOI:10.1016/j.esmoop.2022.100507.

Gregori JG, Miranda EL, Escriva Romani S, Rodriguez BJ, Novoa SA, Morales LF, et al. Time and motion study of a subcutaneous fixed-dose combination of pertuzumab and trastuzumab for the treatment of patients with HER2-positive early breast cancer (PHaTiMa). Cancer Res. 2022; 82(4). DOI:10.1158/1538-7445.SABCS21-OT1-12-09.

Law EH, Galve Calvo E, Wockel A, Parikh R, Kurosky SK, Ansquer VD, et al. European treatment patterns and outcomes associated with first-line CDK4/6 inhibition and hormonal therapies assessed in a real-world non-interventional study (EUCHARIS). Cancer Res. 2022; 82(4). DOI:10.1158/1538-7445.SABCS21-OT2-19-04.

Casas A, Ciruelos E, Oliveira M, Saura C, Bellet M, Pernas S et al. Solti-1903 hope: Real-world clinical practice study to assess the impact of using comprehensive genomic data on the next treatment decision making-choice in patients with locally advanced or metastatic breast cancer in Spain. Cancer Res. 2021; 81(4)

Provencio M, Mazarico Gallego JM, Calles A, Antoñanzas M, Pangua C, Mielgo Rubio X et al. Lung cancer patients with COVID-19 in Spain: GRAVID study. Lung Cancer. 2021; 157: 109-115. DOI:10.1016/j.lungcan.2021.05.014.

Provencio M, Majem M, Guirado M, Massuti B, de Las Penas R, Laura Ortega A et al. Phase II clinical trial with metronomic oral vinorelbine and tri-weekly cisplatin as induction therapy, subsequently concomitant with radiotherapy (RT) in patients with locally advanced, unresectable, non-small cell lung cancer (NSCLC). Analysis of survival and value of ctDNA for patient selection. Lung Cancer. 2021; 153: 25-34. DOI:10.1016/j.lungcan.2021.01.005.

Lopez Santillan M, Lopez E, Alvarez Gonzalez P, Martinez G, Arzuaga Mendez J, Ruiz Diaz I et al. Prognostic and therapeutic value of somatic mutations in diffuse large B-cell lymphoma: A systematic review. Crit Rev Oncol Hematol. 2021; 165: 103430-103430. DOI:10.1016/j.critrevonc.2021.103430.

Ibarrondo O, Álvarez López I, Freundlich F, Arrospide A, Galve Calvo E, Gutiérrez Toribio M, et al. Probabilistic cost-utility analysis and expected value of perfect information for the Oncotype multigenic test: a discrete event simulation model. Gac Sanit. 2020; 34(1): 61-68. DOI:10.1016/j.gaceta.2018.07.012.

Bermejo de Las Heras B, Cortes Ramon Cajal YJ, Galve Calvo E, de la Haba Rodriguez J, Garcia Mata J, Moreno Anton F, et al. The economic burden of metastatic breast cancer in Spain. Eur J Hosp Pharm. 2020; 27(1): 19-24. DOI:10.1136/ejhpharm-2017-001453.

Trigo J, Subbiah V, Besse B, Moreno V, López R, Sala MA, et al. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. Lancet Oncol. 2020; 21(5): 645-654. DOI:10.1016/S1470-2045(20)30068-1.

Carbonero RG, Jimenez Fonseca P, Benavent M, Alonso V, Crespo G, Teule A, et al. WHO Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasm (GEP-NEN): Data from 358 Patients of the Spanish Group of Neuroendocrine and Endocrine Tumors Registry (R-GETNE). Neuroendocrinology. 2020; 110: 72-72

del Prado MPM, Vicente BLD, Arteaga J, Folgueira JL, Cuesta AZ, Diaz FP, et al. Oncotype DX assay's real world data in early stage breast cancer patients. Outcomes of a cohort treated in the Basurto University Hospital, Spain. Cancer Res. 2020; 80(4). DOI:10.1158/1538-7445.SABCS19-P3-14-05.

Barquin M, Calvo V, Garcia F, Nunez B, Sanchez Herrero E, Serna Blasco R, et al. Sex is a strong prognostic factor in stage IV non-small-cell lung cancer patients and should be considered in survival rate estimation. Cancer Epidemiol. 2020; 67. DOI:10.1016/j.canep.2020.101737.

Remon J, Nadal E, Domine M, Ruffinelli J, Garcia Y, Pardo JC, et al. Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer Group. Lung Cancer. 2020; 147: 83-90. DOI:10.1016/j.lungcan.2020.06.034.

Costa EC, Calvo V, Guirado M, Granados A, Castro RL, Rodriguez Abreu D, et al. Small cell lung cancer (SCLC) extensive stage (ES) in Spain: Efficacy of treatments, data from the thoracic tumours registry (TTR study). Ann Oncol. 2020; 31: 1036-1036. DOI:10.1016/j.annonc.2020.08.1547.

Subbiah V, Paz Ares L, Besse B, Moreno V, Zaman K, Gonzalez M, et al. Activity of lurbinectedin in second-line SCLC patients candidates for platinum re-challenge. Ann Oncol. 2020; 31: 1034-1035. DOI:10.1016/j.annonc.2020.08.1545.

Franco F, Costa EC, Rodriguez Abreu D, Castro RL, Dols MC, Guirado M, et al. Description of the clinical characteristics and survival in patients with metastatic NSCLC in the Spanish population: An analysis of the thoracic tumours registry (RTT study). Ann Oncol. 2020; 31: 879-879. DOI:10.1016/j.annonc.2020.08.1694.

Manso L, Hernando C, Galan M, Oliveira M, Cabrera MA, Bratos R, et al. Palbociclib combined with endocrine therapy in heavily pretreated HR+/HER2- advanced breast cancer patients: Results from the compassionate use program in Spain (PALBOCOMP). Breast. 2020; 54: 286-292. DOI:10.1016/j.breast.2020.11.005.

Garcia Campelo R, Arrieta O, Massuti B, Rodriguez Abreu D, Ortega Granados AL, Majem M, et al. Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL). Lung Cancer. 2020; 150: 62-69. DOI:10.1016/j.lungcan.2020.09.018.

Subbiah V, Paz Ares L, Besse B, Moreno V, Peters S, Angeles Sala M, et al. Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment. Lung Cancer. 2020; 150: 90-96. DOI:10.1016/j.lungcan.2020.10.003.

De Jesus Acosta A, Crespo Herrero G, Gomez Dorronsoro ML, Alonso V, Riesco Martinez MC, Custodio A, et al. SILVELUL project: Immunohistochemical panel analyses as potential predictive and prognostic factors in pancreatic neuroendocrine tumours (PanNET) treated with CAPTEM or everolimus. Ann Oncol. 2019; 30(5)

Valderrama BP, Perez Ramirez S, Rodriguez Vida A, Gonzalez del Alba A, Mendez Vidal MJ, Vazquez Estevez S, et al. SPAZO2 (SOGUG): Outcomes and prognostic significance of IMDC intermediate prognosis subclassification in metastatic renal cell carcinoma (mRCC) in patients treated with 1st-line pazopanib (1stPz). Ann Oncol. 2019; 30(5): 385-385

Guirado M, Majem M, Sureda BM, Bataller RD, Granados A, Casado M, et al. NORA trial (GECP 15/02): Updated results of the Spanish Lung Cancer Group (SLCG) phase II trial of concurrent chemo-radiotherapy (CT-RT) with cisplatin (P) plus metronomic oral vinorelbine (mOV) for unresectable locally advanced non-small cell lung cancer (LA-NSCLC). Ann Oncol. 2019; 30: 594-594

Costa EC, Guirado M, Herrero CJC, Barrera JB, Garcia Campelo MR, Granados A, et al. Tobacco use in lung cancer (LC) patients (p) in Spain. Ann Oncol. 2019; 30: 749-749

Abreu DR, Guirado M, Herrero CJC, Barrera JB, Bernabe R, Casal J, et al. Biomarker testing of lung cancer in Spain. Ann Oncol. 2019; 30

Carcereny E, Franco F, Rodriguez Abreu D, Castro RL, De Las Penas R, Guirado M, et al. Smoking Habit in Lung Cancer in Spain. J Thorac Oncol. 2019; 14(10): 784-785. DOI:10.1016/j.jtho.2019.08.1686.

Provencio M, Franco F, Sanchez Hernandez A, Romero ES, Giron CG, Domine M, et al. Liquid Biopsy: Association Between the Burden of Disease in Patients with EGFR-Mutated NSCLC and the Frequency of Its Detection in Blood. J Thorac Oncol. 2019; 14(10): 751-751. DOI:10.1016/j.jtho.2019.08.1609.

Rodriguez Abreu D, Moran T, Castro RL, Guirado M, Camps C, Nunez B, et al. Analysis of Biomarkers in Lung Cancer in Spain. J Thorac Oncol. 2019; 14(10): 752-752. DOI:10.1016/j.jtho.2019.08.1611.

Herrero ES, Franco F, Auglite M, Blasco RS, Del Romo MB, Sanchez Hernandez A, et al. ctDNA Levels Significantly Predicts Survival in NSCLC Patients with an EGFR Activating Mutation. J Thorac Oncol. 2019; 14(10): 696-696. DOI:10.1016/j.jtho.2019.08.1480.

Perez JMT, Subbiah V, Besse B, Moreno V, Lopez R, Sala MA, et al. Antitumor Activity of Single Agent Lurbinectedin in Patients with Relapsed SCLC Occurring >= 30 Days After Last Platinum Dose. J Thorac Oncol. 2019; 14(10): 535-535